+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 1Year - 40Years
All Genders
ID05292664

Phase I Study of Venetoclax with Chemotherapy for Children, Adolescents, and Young Adults with High-Risk Blood Cancers

Led by Andrew E. Place, MD · Updated on 2026-03-12

30

Participants Needed

5

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and tolerability of venetoclax combined with chemotherapy in children and young adults with high-risk blood cancers, including myelodysplastic syndrome MDS, acute myeloid leukemia AML derived from MDS, and acute lymphoblastic leukemia ALL or lymphoblastic lymphoma LBL. This phase I trial aims to find the safest dose of venetoclax that can be given with standard chemotherapy drugs. The study includes three separate patient groups based on their specific blood cancer type and genetic risk factors. Participants receive different drug combinations depending on their disease group. In Cohorts A and B MDSAML patients, treatment cycles last about 28 days and include venetoclax and azacitidine daily on set days, with additional chemotherapy drugs given if leukemia cells are detected in the spinal fluid. Cohort B involves patients with genetic conditions increasing treatment toxicity risk. Cohort C includes patients with relapsed or refractory ALL or LBL, receiving a single 32-day treatment cycle with venetoclax plus several chemotherapy drugs including dexamethasone, vincristine, doxorubicin, and calaspargase pegol, with adjustments for allergies. Participants undergo screening, treatment visits, and follow-up assessments throughout the study. Researchers monitor the maximum tolerated dose, treatment-related side effects, and response to therapy. Outcome measures include remission rates, overall survival, and event-free survival up to two years. Safety is carefully tracked during and after treatment, including monitoring for toxicities related to specific drugs. The total participation time depends on the cohort and treatment cycles assigned.

CONDITIONS

Brief Title

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Research Team

A

Andrew E Place, MD, PhD

J

Jessica A Pollard, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here